Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | PRKCG | P05129 | 1/20 | 0.71 |
| ▸ | PRKCB | P05771 | 1/20 | 0.71 |
| ▸ | PRKCA | P17252 | 1/20 | 0.71 |
| ▸ | PRKCH | P24723 | 1/20 | 0.71 |
| ▸ | PRKCI | P41743 | 1/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.71 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.71 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | GMNN | O75496 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8643482 | 1.00 | AKT1 (0.71) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL7645611 | 1.00 | AKT1 (0.71) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL8008187 | 1.00 | AKT1 (0.71) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL7950243 | 1.00 | AKT1 (0.71) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL8007906 | 1.00 | AKT1 (0.71) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL2734470 | 1.00 | AKT1 (0.71) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL8009671 | 1.00 | AKT1 (0.71) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL8642035 | 1.00 | AKT1 (0.71) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL2128906 | 0.99 | AKT1 (0.69) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL5711833 | 0.93 | ALDH1A1 (0.65) | AKT1LMNAALDH1A1PRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1818 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4456882-B1 | LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA | BioNTech SE (DE) | 2026-05-13 | — | — | EP | claimed |
| US-20260125681-A1 | DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF | HANGZHOU TIANLONG PHARMACEUTICAL CO., LTD. (CN) | 2026-05-07 | — | — | US | claimed |
| EP-4736848-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF | Shanghai Regenelead Therapies Co., Ltd. (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-4737436-A1 | CATIONIC LIPID CONTAINING TWO TERTIARY AMINE GROUPS, AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-4731606-A1 | IONIZABLE THIOLIPIDS AND USES THEREOF | BioNTech SE (DE) | 2026-04-29 | — | — | EP | claimed |
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4726038-A1 | EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE | Rinuagene Biotechnology Co., Ltd. (CN) | 2026-04-15 | — | — | EP | claimed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3247363-A1 | LIPID NANOPARTICLE COMPOSITIONS | Moderna Therapeutics, Inc. (US) | 2017-11-29 | — | — | EP | claimed |
| EP-3247398-A1 | LIPID NANOPARTICLE COMPOSITIONS | Moderna Therapeutics, Inc. (US) | 2017-11-29 | — | — | EP | claimed |
| WO-2017201317-A1 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-17 | — | — | US | claimed |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-10 | — | — | US | claimed |
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | claimed |
| WO-2017127750-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2017-07-27 | — | — | WO | claimed |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | claimed |
| WO-2016118724-A1 | LIPID NANOPARTICLE COMPOSITIONS | MODERNA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | WO | claimed |
| WO-2016118725-A1 | LIPID NANOPARTICLE COMPOSITIONS | MODERNA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | AKT1 1618/4885LMNA 1539/4885ALDH1A1 4530/4885 |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | AKT1 1618/4885LMNA 1539/4885ALDH1A1 4530/4885 |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PCTP, PLTP | AKT1 1625/4885LMNA 266/4885ALDH1A1 4411/4885 |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PHOSPHO1, LIPC, SDCBP | AKT1 3029/4885LMNA 455/4885ALDH1A1 4429/4885 |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | AKT1 1618/4885LMNA 1539/4885ALDH1A1 4530/4885 |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | AKT1 1618/4885LMNA 1539/4885ALDH1A1 4530/4885 |
| US-20260125681-A1 | DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF | NSUN2, EIF2AK2, METTL16 | AKT1 2457/4885LMNA 994/4885ALDH1A1 4251/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | AKT1 2618/4885LMNA 481/4885ALDH1A1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.